Latest Vertex Pharmaceuticals News & Updates

See the latest news and media coverage for Vertex. We track all announcements, press releases, and industry mentions in real time, all in one place.

Vertex Pharmaceuticals (Vertex)

Biopharmaceutical company developing medicines for serious diseases

vrtx.com

Headquarters: Boston, United States
Founded year: 1989
Company type: Public company
Number of employees: 6,600–10,000
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Vertex Pharmaceuticals (Vertex)

In short: Vertex secured UK approval for Casgevy in children aged five and older.

Company announcements

October 23 Vertex

Vertex Publishes Phase 3 RAINIER Results for Povetacicept

Data published in NEJM shows significant efficacy and favorable safety. FDA approval decision is due by November 30.

October 20 Vertex

Vertex appoints Daniel Brennan to its board of directors

Daniel Brennan joins the Audit and Finance Committee on October 20, 2026, receiving a restricted stock unit award.

October 9 Vertex

Vertex presents new ALYFTREK data showing pancreatic function recovery in young children

Interim data from a 2 to 5-year-old study shows that early intervention with vanzacaftor/tezacaftor/deutivacaftor can reverse exocrine pancreatic insufficiency and allow PERT discontinuation.

September 22 Vertex

Vertex reports AMPLIFIED trial progress

Positive Phase 2b results and completed Phase 2/3 enrollment demonstrate advancement in APOL1-mediated kidney disease research.

Media coverage

Yesterday MarketScreener

UK Healthcare Regulator OKs Vertex Pharmaceuticals' Casgevy Gene Therapy for Children From Age Five

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.

October 23 Benzinga

Vertex Pharmaceuticals Announces Phase 3 RAINIER Results Supporting Potential Of Povetacicept In IgA Neph

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for...

October 15 BioWorld

Abbvie, Vertex lead $32B September biopharma M&A surge

Biopharma deals, excluding M&As, reached $224.91 billion in the first nine months of 2026, up 5% from $213.62 billion during the same period in 2025...

October 1 BioSpace

M&A slows in Q3 but Vertex snags one of the year's biggest in $10B Crinetics buy

After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.

Never miss news about Vertex

Track Vertex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Vertex competitors & trending companies

Browse news for competitors to Vertex and other trending companies.